Decision Resources Research Reports

Title	Published	Price
Innovation, Health Technology Assessment, and Comparative Effectiveness Research: The Obstacle Course to Market Access By: Decision Resources Introduction: The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for comparative effectiveness research (CER) as part of its planned overhaul \| more...	9/25/2009	$2,250.00
Pharmaceutical Pricing and Reimbursement in India By: Decision Resources Introduction Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies are looking to substantially increase their sales in India and other emerging markets. The Indian market is growing by more \| more...	9/25/2009	$2,250.00
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment? By: Decision Resources Introduction “I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many sarcoidosis patients require little or no treatment, but patients with chronic disease need a \| more...	9/23/2009	$4,500.00
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff? By: Decision Resources Introduction Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity? Many major companies are reorganizing the research branches of their businesses \| more...	9/18/2009	$2,250.00
Disruption or Advantage? Update on Companion Diagnostics By: Decision Resources Introduction Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders. Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development is huge because companion \| more...	9/15/2009	$2,250.00
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry By: Decision Resources The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry are \| more...	9/15/2009	$2,250.00
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry By: Decision Resources In this report we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and a research fellow at the American Enterprise Institute, who testifi ed before the U.S. House Judiciary Committee’s \| more...	9/10/2009	$2,250.00
Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009 By: Decision Resources The first Phase 0 trial results, thefirst fruits of Japan’s biosimilar pathway, the first straightforward use of the social marketing tool Twitter to advance a drug franchise, thefirst moves of the EU to regulate third-party \| more...	9/10/2009	$2,250.00
The Pricing and Reimbursement Environment for Neurology Drugs By: Decision Resources Introduction: Neurological disorders will impose a growing social and financial burden on the major pharmaceutical markets as the elderly population in these countries increases steadily. Governments and other payers recognize the pressing need to tackle \| more...	8/31/2009	$2,250.00
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec By: Decision Resources Introduction Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis’s Gleevec/Glivec [imatinib]), significant \| more...	8/27/2009	$2,250.00
Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases By: Decision Resources Introduction Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated with these diseases do not constitute a large marketplace. Although researchers are working to discover biomarkers, associate \| more...	8/21/2009	$2,250.00
Neurological Disease: Early-Stage R&D and Dealmaking By: Decision Resources Introduction How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and \| more...	8/20/2009	$2,250.00
Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics? By: Decision Resources Introduction The point-of-care (POC) diagnostics segment of the in vitro diagnostics fi eld once largely consisted of glucosemonitoring devices. With billions of dollars generated in revenue in the United States alone, POC testing has blossomed \| more...	8/20/2009	$2,250.00
Special Report - The Autism Spectrum Disorders Market: Substantial Opportunity and Unique Challenges By: Decision Resources Introduction An increase in public funding for research and a heightened interest among drug developers suggest that a breakthrough in autism spectrum disorder (ASD) treatment may be imminent. However, drug development has been slow, plagued \| more...	8/18/2009	$4,500.00
Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009 By: Decision Resources Introduction The second quarter of 2009 saw steady progress toward healthcare reform in the United States and action in several of the world’s other major pharmaceutical markets to curb pharmaceutical expenditures. Cost-containment strategies vary considerably \| more...	8/6/2009	$2,250.00
The Neurology Pipeline: A Strategic Review By: Decision Resources Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one of the motivations \| more...	8/3/2009	$2,250.00
Strategies for Building Early-Stage Pipelines Through External Sources By: Decision Resources Introduction Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity, pharmaceutical companies are seeking external sources of products and innovation. Biotech companies offer valuable technologies, targets, and compounds. Pharma companies best able \| more...	7/30/2009	$2,250.00
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases By: Decision Resources Introduction Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and redundant biological pathways are holding \| more...	7/27/2009	$2,250.00
The Psychiatric Disease Pipeline: A Strategic Review By: Decision Resources Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in recent years, sustained franchise sales, tolerance for use \| more...	7/22/2009	$2,250.00
Pharmaceutial Pricing and Reimbursement in China By: Decision Resources Introduction With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third largest in the world in 2011. A radical healthcare reform package recently unveiled by \| more...	6/29/2009	$2,250.00
The Pricing and Reimbursement Environment for Immune Disease Therapies By: Decision Resources Introduction Drug therapies for immune disorders span an enormous price range—from a few cents per day to tens of thousands of dollars per year. Not surprisingly, payers impose restrictions on the use of the most \| more...	6/25/2009	$2,250.00
Special Report: 2009 Chartbook of International Pharmaceutical Prices By: Decision Resources Introduction Payers in all countries are increasing their pressure on manufacturers to cut prices. But prescription drug pricing and reimbursement policies vary markedly among the leading pharmaceutical markets, so, to best determine pricing, pharmaceutical companies \| more...	6/23/2009	$4,500.00
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement? By: Decision Resources Introduction For decades, the efficacy of hormone replacement therapy (HRT) for some of menopause’s most troublesome symptoms eliminated any incentive to develop new approaches to treatment. However, data questioning the safety of estrogen-containing therapies have \| more...	6/20/2009	$2,250.00
Key Trends Fueling the Boom in Genetic Testing By: Decision Resources Introduction “Progress” aptly describes the expanding field of genetic testing. The field is more than finding linkages of genes with diseases: it encompasses technologies that have made it easier to quickly and more efficiently discover \| more...	6/15/2009	$2,250.00
SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis By: Decision Resources Introduction Although interviewed thought leaders acknowledge that available biological therapies have greatly improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease in children—they do not hesitate to point out unmet needs and remaining \| more...	6/12/2009	$4,500.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/8/2009 - 3